https://graniterecord.org/bill/2024/hb513.html relative to affordability and safety of clinician administered drugs. en-us Tue, 08 Sep 2026 00:00:00 +0000 https://graniterecord.org/bill/2024/hb513.html2023-2024:HB513:2024-10-31:interim-study-report-not-recommended-forThu, 31 Oct 2024 00:00:00 +0000relative to affordability and safety of clinician administered drugs. Interim Study Report: Not Recommended for Future Legislation (Vote 16-0) Status: House: INTERIM STUDY https://graniterecord.org/bill/2024/hb513.html2023-2024:HB513:2024-10-17:executive-session-10-17-2024-10-00-am-loThu, 17 Oct 2024 00:00:00 +0000relative to affordability and safety of clinician administered drugs. Executive Session: 10/17/2024 10:00 am LOB 302-304 Status: House: INTERIM STUDY https://graniterecord.org/bill/2024/hb513.html2023-2024:HB513:2024-09-12:full-committee-work-session-09-12-2024-1Thu, 12 Sep 2024 00:00:00 +0000relative to affordability and safety of clinician administered drugs. Full Committee Work Session: 09/12/2024 10:00 am LOB 302-304 Status: House: INTERIM STUDY https://graniterecord.org/bill/2024/hb513.html2023-2024:HB513:2024-01-03:refer-for-interim-study-ma-vv-01-03-2024Wed, 03 Jan 2024 00:00:00 +0000relative to affordability and safety of clinician administered drugs. Refer for Interim Study: MA VV 01/03/2024 Status: House: INTERIM STUDY https://graniterecord.org/bill/2024/hb513.html2023-2024:HB513:2023-11-08:executive-session-11-08-2023-01-30-pm-loWed, 08 Nov 2023 00:00:00 +0000relative to affordability and safety of clinician administered drugs. Executive Session: 11/08/2023 01:30 pm LOB 302-304 Status: House: INTERIM STUDY https://graniterecord.org/bill/2024/hb513.html2023-2024:HB513:2023-11-08:committee-report-refer-for-interim-studyWed, 08 Nov 2023 00:00:00 +0000relative to affordability and safety of clinician administered drugs. Committee Report: Refer for Interim Study 11/08/2023 (Vote 19-0; CC) Status: House: INTERIM STUDY https://graniterecord.org/bill/2024/hb513.html2023-2024:HB513:2023-09-20:subcommittee-work-session-09-20-2023-01-Wed, 20 Sep 2023 00:00:00 +0000relative to affordability and safety of clinician administered drugs. Subcommittee Work Session: 09/20/2023 01:15 pm LOB 302-304 Status: House: INTERIM STUDY https://graniterecord.org/bill/2024/hb513.html2023-2024:HB513:2023-03-15:executive-session-03-15-2023-11-00-am-loWed, 15 Mar 2023 00:00:00 +0000relative to affordability and safety of clinician administered drugs. Executive Session: 03/15/2023 11:00 am LOB 302-304 Status: House: INTERIM STUDY https://graniterecord.org/bill/2024/hb513.html2023-2024:HB513:2023-03-15:subcommittee-work-session-03-15-2023-10-Wed, 15 Mar 2023 00:00:00 +0000relative to affordability and safety of clinician administered drugs. Subcommittee Work Session: 03/15/2023 10:05 am LOB 302-304 Status: House: INTERIM STUDY https://graniterecord.org/bill/2024/hb513.html2023-2024:HB513:2023-03-15:retained-in-committeeWed, 15 Mar 2023 00:00:00 +0000relative to affordability and safety of clinician administered drugs. Retained in Committee Status: House: INTERIM STUDY https://graniterecord.org/bill/2024/hb513.html2023-2024:HB513:2023-03-08:subcommittee-work-session-03-08-2023-10-Wed, 08 Mar 2023 00:00:00 +0000relative to affordability and safety of clinician administered drugs. Subcommittee Work Session: 03/08/2023 10:00 am LOB 302-304 Status: House: INTERIM STUDY https://graniterecord.org/bill/2024/hb513.html2023-2024:HB513:2023-03-08:executive-session-03-08-2023-01-15-pm-loWed, 08 Mar 2023 00:00:00 +0000relative to affordability and safety of clinician administered drugs. Executive Session: 03/08/2023 01:15 pm LOB 302-304 Status: House: INTERIM STUDY https://graniterecord.org/bill/2024/hb513.html2023-2024:HB513:2023-02-15:public-hearing-02-15-2023-02-00-pm-lob-3Wed, 15 Feb 2023 00:00:00 +0000relative to affordability and safety of clinician administered drugs. Public Hearing: 02/15/2023 02:00 pm LOB 302-304 Status: House: INTERIM STUDY https://graniterecord.org/bill/2024/hb513.html2023-2024:HB513:2023-01-05:introduced-in-recess-of-01-05-2023-and-rThu, 05 Jan 2023 00:00:00 +0000relative to affordability and safety of clinician administered drugs. Introduced (in recess of) 01/05/2023 and referred to Commerce and Consumer Affairs Status: House: INTERIM STUDY